Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections – Pipeline Review, H1 2017, provides an overview of the Marburgvirus Infections (Infectious Disease) pipeline landscape.
Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Marburgvirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 11 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.
Marburgvirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Marburgvirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Marburgvirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Arno Therapeutics Inc
BioCryst Pharmaceuticals Inc
Emergent BioSolutions Inc
Fab'entech SA
GeoVax Labs Inc
Integrated BioTherapeutics Inc
Johnson & Johnson
Microbiotix Inc
NanoViricides Inc
Profectus BioSciences Inc
Rodos BioTarget GmbH
Sarepta Therapeutics Inc
Vaxart Inc
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Overview
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Companies Involved in Therapeutics Development
Arno Therapeutics Inc
BioCryst Pharmaceuticals Inc
Emergent BioSolutions Inc
Fab'entech SA
GeoVax Labs Inc
Integrated BioTherapeutics Inc
Johnson & Johnson
Microbiotix Inc
NanoViricides Inc
Profectus BioSciences Inc
Rodos BioTarget GmbH
Sarepta Therapeutics Inc
Vaxart Inc
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drug Profiles
(Ebola + Marburg) (monovalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola + Marburg) (trivalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola + Marburg) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola [Sudan, Zaire] + Marburg) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola [Sudan] + Marburg) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
1-E703 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies for Ebola and Marburg Viral Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-12 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-5 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVI-7288 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galidesivir – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GOVXE-301 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GOVXE-302 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marburg vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Ebola and Marburg Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Marburg Virus – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-78 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-026 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBT-05 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ebola and Marburg Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ebola and Marburg Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ebola and Marburg Virus Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Dormant Projects
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Discontinued Products
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Product Development Milestones
Featured News & Press Releases
Jan 19, 2016: Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial
Nov 17, 2015: Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus
Sep 08, 2015: GeoVax Ebola Vaccine Proven Effective in Rodent Models
Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform
May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
Apr 08, 2015: Profectus BioSciences Ebola Vaccine Shown Effective and Safe in Providing Rapid, Single-Dose Protection Against Current "Makona" Ebola Outbreak Strain in Non-Human Primates
Mar 31, 2015: BioCryst Awarded BCX4430 Advanced Development Contract
Mar 25, 2015: IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies
Jan 22, 2015: NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
Dec 23, 2014: BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection
Oct 31, 2014: Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses
Oct 27, 2014: NanoViricides Signs CRADA for Material Transfer with USAMRIID for Evaluating Its Anti-Ebola Drug Candidates
Sep 18, 2014: BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases
Jul 31, 2014: UTMB researchers receive over $6 million to develop treatment for deadly Ebola and Marburg viruses
Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Arno Therapeutics Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by BioCryst Pharmaceuticals Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Emergent BioSolutions Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Fab'entech SA, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by GeoVax Labs Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Integrated BioTherapeutics Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Johnson & Johnson, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Microbiotix Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by NanoViricides Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Profectus BioSciences Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Rodos BioTarget GmbH, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Sarepta Therapeutics Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Vaxart Inc, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Dormant Projects, H1 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
